中關村(000931.SZ)與佳木斯市高新技術產業開發區管理委員會達成合作協議
格隆匯 9 月 29日丨中關村(000931.SZ)公佈，為實現雙方合作共贏，充分發揮公司在“醫藥大健康”及相關領域的人才、技術、資金等優勢，全面深化戰略合作，經友好協商，2020年9月26日，公司與佳木斯市高新技術產業開發區管理委員會達成合作協議。此次合作內容如下：
(1)合力推進多多藥業有限公司(公司之全資子公司北京中關村四環醫藥開發有限責任公司持有多多藥業有限公司69.26%股權，以下簡稱：多多藥業)做大做強。乙方爭取將總部研發的醫藥新品種更多向多多藥業轉移，推進多多藥業擴大生產、延伸產業鏈。乙方同意首期提供蒙脱石散等醫藥新產品，並適時給予5000萬元資金支持用於多多藥業改造升級。甲方積極爭取省、市政策資金給予多多藥業支持，為企業打造優質的環境。多多藥業力爭三年內實現當年上繳税金達到1億元。
(2)謀劃建設中關村佳木斯醫藥大健康產業園。甲方支持乙方重組佳木斯高新區相關企業，或重新規劃用地，拓建中關村佳木斯醫藥大健康產業園，爭取投資2億元，發展醫藥、藥食同源及大健康產品。
(3)開展健康醫養合作。依託乙方在康養領域先進的模式與成功經驗，以佳木斯高新區內東興養老機構為切入點謀求合作事宜，打造中高端康養示範工程。並進一步探討建立康養小鎮與康養社區合作。
(4)開展更廣泛的合作。雙方進一步探討在現代農業、老舊小區適老化改造等領域開展更廣範圍和更深層次的合作，尋求共贏。按照“成熟一個，落實一個”的思路，在後續工作及具體項目的合作協議中進一步明確。
通過此次與佳木斯市高新技術產業開發區管理委員會達成《合作協議》，有利於公司在佳木斯深耕“醫藥大健康”及相關領域，獲得政府給予的支持，助力公司主業發展。此次合作相關事宜僅為雙方對合作方式、領域達成的初步意向，鑑於項目投資合作協議、建設合同尚未簽訂，存在不確定性，對公司當期及未來業績的影響尚無法判斷。敬請廣大投資者理性投資，注意風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
